Zobrazeno 1 - 10
of 83
pro vyhledávání: '"André Baruchel"'
Autor:
Elizabeth Fox, Michael Berntgen, Alfonso Quintás-Cardama, Veronique Minard-Colin, Susan L. Weiner, André Baruchel, Laura Pearce, Karsten Nysom, Andrew D.J. Pearson, Danielle H. Taylor, Christian M. Zwaan, Nirali N. Shah, Yousif Matloub, Ivan D. Horak, Gregory H. Reaman, Gilles Vassal, Koen Norga, Claudia Rossig, Dominik Karres, Lori A. Ehrlich, Martina Schüßler-Lenz, Alberto S. Pappo, Joe McDonough, Martina A. Sersch, Nick Richardson, Donna Ludwinski, Abraham Bassan, Eric Bleickardt, Nicole Scobie, Stephen Gottschalk, Rob Pieters, Sarah K. Tasian, Courtney Johnson, Teresa de Rojas, Malcolm A. Smith, Franca Ligas, Lynley V. Marshall, Shannon L. Maude, Brenda J. Weigel, Nick Bird, Najat Bouchkouj, Behzad K. Masouleh, Sarah Beaussant Cohen, Delphine Heenen, Rosanna Ricafort, G. Lesa, Linda Hanssens, Peter F. Bross, Carrie Brownstein, Crystal L. Mackall, Martin Pule, Douglas S. Hawkins, Jaroslav Sterba, Maksim Mamonkin
Publikováno v:
European Journal of Cancer. 160:112-133
The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially B-cell precu
Autor:
Franck Morschhauser, Florence Rabian, Catherine Thieblemont, Marie-Thérèse Rubio, Guillaume Cartron, David Beauvais, Steven Le Gouill, Jacques-Olivier Bay, André Baruchel, Sabine Furst, Gandhi Damaj, Denis Caillot, Emmanuel Bachy, Ibrahim Yakoub-Agha
Publikováno v:
Bulletin du Cancer
Bulletin du Cancer, John Libbey Eurotext, 2021, 108 (7-8), pp.725-729. ⟨10.1016/j.bulcan.2020.10.017⟩
Bulletin du Cancer, 2021, 108 (7-8), pp.725-729. ⟨10.1016/j.bulcan.2020.10.017⟩
Bulletin du Cancer, John Libbey Eurotext, 2021, 108 (7-8), pp.725-729. ⟨10.1016/j.bulcan.2020.10.017⟩
Bulletin du Cancer, 2021, 108 (7-8), pp.725-729. ⟨10.1016/j.bulcan.2020.10.017⟩
International audience; The chimeric antigen receptor T-cells are a new class of anticancer treatment consisting in genetically modifying autologous or allogenic T-cells to make express a CAR directed against a membrane tumor antigen. In Europe, tisa
Autor:
Arnaud Petit, Etienne Lengliné, Stéphane Ducassou, Elizabeth Macintyre, Françoise Huguet, Nicolas Boissel, Virginie Gandemer, Norbert Ifrah, Jean-Michel Cayuela, Guillaume Andrieu, Vahid Asnafi, Aline Schmidt, Nathalie Grardel, Isabelle Arnoux, Carlos Graux, Christophe Bontoux, Marie-Emilie Dourthe, Mathieu Simonin, Hervé Dombret, Ludovic Lhermitte, André Baruchel
Publikováno v:
Journal of Hematology and Oncology
Journal of Hematology and Oncology, BioMed Central, 2021, 14 (1), ⟨10.1186/s13045-021-01068-4⟩
Journal of hematology & oncology, Vol. 14, no. 1, p. 74 [1-7] (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-7 (2021)
Journal of Hematology and Oncology, 2021, 14 (1), ⟨10.1186/s13045-021-01068-4⟩
Journal of Hematology and Oncology, BioMed Central, 2021, 14 (1), ⟨10.1186/s13045-021-01068-4⟩
Journal of hematology & oncology, Vol. 14, no. 1, p. 74 [1-7] (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-7 (2021)
Journal of Hematology and Oncology, 2021, 14 (1), ⟨10.1186/s13045-021-01068-4⟩
IDH1 and IDH2 mutations (IDH1/2Mut) are recognized as recurrent genetic alterations in acute myeloid leukemia (AML) and associated with both clinical impact and therapeutic opportunity due to the recent development of specific IDH1/2Mut inhibitors. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74e6922d8b35993655037e3a8812c470
https://hal.sorbonne-universite.fr/hal-03218266/file/s13045-021-01068-4.pdf
https://hal.sorbonne-universite.fr/hal-03218266/file/s13045-021-01068-4.pdf
Autor:
Aline Tanguy-Schmidt, Sébastien Maury, Paola Ballerini, Nicolas Sirvent, Judith Landman-Parker, Patrice Chevallier, E. Dore, Cédric Duclos, Ibrahima Ba, Hélène Cavé, Jean Soulier, Massimiliano Bonifacio, Nicolas Duployez, Chantal Himberlin, André Baruchel, Hervé Dombret, Thorsten Braun, Ilaria Tanasi, Emmanuelle Clappier, Jerome Tamburini, Nicolas Boissel, Wendy Cuccuini, Philippe Rousselot
Publikováno v:
Blood
Blood, American Society of Hematology, 2019, 134 (16), pp.1351-1355. ⟨10.1182/blood.2019001244⟩
Blood, American Society of Hematology, 2019, 134 (16), pp.1351-1355. ⟨10.1182/blood.2019001244⟩
Tanasi et al present a prospective strategy for identifying patients with Philadelphia-like acute lymphoblastic leukemia, demonstrating the efficacy of early introduction of tyrosine kinase inhibitors in improving outcomes.
Autor:
Guy Leverger, Odile Fenneteau, Arnaud Petit, Charlotte Calvo, Francoise Mechinaud, André Baruchel
Publikováno v:
Cancers
Cancers, MDPI, 2021, 13 (4), pp.777. ⟨10.3390/cancers13040777⟩
Cancers, Vol 13, Iss 777, p 777 (2021)
Cancers, MDPI, 2021, 13 (4), pp.777. ⟨10.3390/cancers13040777⟩
Cancers, Vol 13, Iss 777, p 777 (2021)
Simple Summary Infant acute myeloid leukemia (AML) is a rare subgroup of AML of pediatric patients under two years of age. For a long time, they have been included in pediatric forms of AML. However, infant AML demonstrates unusual clinical and biolo
Autor:
Paul Bastard, Aurélien Galerne, Alain Lefevre-Utile, Coralie Briand, André Baruchel, Philippe Durand, Judith Landman-Parker, Elodie Gouache, Nathalie Boddaert, Despina Moshous, Joel Gaudelus, Robert Cohen, Georges Deschenes, Alain Fischer, Stéphane Blanche, Loïc de Pontual, Bénédicte Neven
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Frontiers in Immunology
Frontiers in Immunology, Frontiers, 2020, 11, ⟨10.3389/fimmu.2020.595478⟩
Frontiers in Immunology, 2020, 11, ⟨10.3389/fimmu.2020.595478⟩
Frontiers in Immunology
Frontiers in Immunology, Frontiers, 2020, 11, ⟨10.3389/fimmu.2020.595478⟩
Frontiers in Immunology, 2020, 11, ⟨10.3389/fimmu.2020.595478⟩
International audience; Primary infection with varicella-zoster virus (VZV) causes chickenpox, a benign and self-limited disease in healthy children. In patients with primary or acquired immunodeficiencies, primary infection can be life-threatening,
Autor:
Jean-Michel Cayuela, Nathalie Grardel, Norbert Ifrah, Carlos Graux, Elizabeth Macintyre, Marie-Emilie Dourthe, Nicolas Boissel, Virginie Gandemer, Hervé Dombret, Vahid Asnafi, Ludovic Lhermitte, Isabelle Arnoux, Arnaud Petit, André Baruchel, Etienne Lengliné, Mathieu Simonin
Publikováno v:
Blood
Blood, 2021, 137 (12), pp.1690-1694. ⟨10.1182/blood.2020007959⟩
Blood, American Society of Hematology, 2021, 137 (12), pp.1690-1694. ⟨10.1182/blood.2020007959⟩
Blood, Vol. 137, no. 12, p. 1690-1694 (2021)
Blood, 2021, 137 (12), pp.1690-1694. ⟨10.1182/blood.2020007959⟩
Blood, American Society of Hematology, 2021, 137 (12), pp.1690-1694. ⟨10.1182/blood.2020007959⟩
Blood, Vol. 137, no. 12, p. 1690-1694 (2021)
TO THE EDITOR: T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are aggressive neoplasms that result from the proliferation of T-lymphoid progenitors blocked at thymic stages of differentiation. They account for 1
Autor:
Jennifer Osman, André Baruchel, Bruno Cassinat, Odile Fenneteau, Jean-Hugues Dalle, Sabrina Pereira, Linda Ariza-McNaughton, Marion Strullu, Fernando Anjos-Afonso, Christine Chomienne, Chloé Arfeuille, Dominique Bonnet, Hélène Cavé, Kevin Rouault-Pierre, Elodie Lainey, Aurélie Caye, Erin Currie, Ander Abarrategi, Vincent Barlogis
Publikováno v:
Leukemia
Juvenile myelomonocytic leukemia (JMML) is a rare aggressive myelodysplastic/myeloproliferative neoplasm of early childhood, initiated by RAS-activating mutations. Genomic analyses have recently described JMML mutational landscape; however, the natur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bec5a2a4601a5cde780d9060e3819af
Autor:
Eden Schwartz, Nicolas Boissel, Anne Brignier, Isabelle Madelaine, Nathalie Parquet, André Desproges, Sarah Mukenyi, Lorène Magdelonnette, Chloé Talarmin, Emmanuelle Lesprit, André Baruchel, Catherine Thieblemont, Steven Kerob, Jérôme Larghero, Miryam Mebarki, François Cartier
Publikováno v:
Cytotherapy
Cytotherapy, Elsevier, 2020, 22, pp.792-801. ⟨10.1016/j.jcyt.2020.06.009⟩
Cytotherapy, 2020, 22, pp.792-801. ⟨10.1016/j.jcyt.2020.06.009⟩
Cytotherapy, Elsevier, 2020, 22, pp.792-801. ⟨10.1016/j.jcyt.2020.06.009⟩
Cytotherapy, 2020, 22, pp.792-801. ⟨10.1016/j.jcyt.2020.06.009⟩
International audience; Background aims: According to European Directive 2001/83/EC, chimeric antigen receptor T (CAR T) cells belong to a new class of medicines referred to as advanced therapy medicinal products (ATMPs). The specific features and co
Autor:
Brigitte Nelken, Yves Bertrand, Krzysztof Kałwak, Frédéric Millot, André Baruchel, Meinolf Suttorp, A. B. Versluys, Stéphane Ducassou
Publikováno v:
European Journal of Cancer
European Journal of Cancer, Elsevier, 2020, 136, pp.107-112. ⟨10.1016/j.ejca.2020.05.020⟩
European Journal of Cancer, Elsevier, 2020, 136, pp.107-112. ⟨10.1016/j.ejca.2020.05.020⟩
Background Ponatinib is effective in adults with Philadelphia chromosome–positive (Ph+) leukaemias, but scant data are available regarding the use of this tyrosine kinase inhibitor in children. Aims The aim of this study isto describe the tolerance